Efmoroctocog alfa is a medication used in the treatment of hemophilia A. Hemophilia A is a condition where the blood does not clot properly due to a lack of a specific protein. This medication helps to replace the missing protein, allowing the blood to clot more effectively. In this clinical trial, efmoroctocog alfa is used as a preventive treatment to help reduce bleeding episodes and improve joint health over time.

Eftrenonacog alfa is a medication used for treating hemophilia B, which is similar to hemophilia A but involves a different missing protein. This medication works by providing the body with the protein it lacks, helping the blood to clot properly. In the trial, eftrenonacog alfa is used as a preventive measure to help manage bleeding and protect joint health in patients with hemophilia B.

Hemophilia A – Hemophilia A is a genetic disorder caused by a deficiency of clotting factor VIII, which is essential for blood clotting. This condition leads to prolonged bleeding after injuries, surgeries, or even spontaneously. Over time, repeated bleeding episodes can cause damage to joints, muscles, and other tissues. The disease primarily affects males, as it is linked to the X chromosome. Individuals with Hemophilia A may experience frequent nosebleeds, easy bruising, and excessive bleeding from cuts or injuries. Joint bleeding is common, leading to pain and swelling.

Hemophilia B – Hemophilia B is a genetic disorder resulting from a deficiency of clotting factor IX, which is crucial for proper blood coagulation. Similar to Hemophilia A, this condition causes prolonged bleeding after injuries or surgeries and can also occur spontaneously. The disease is inherited in an X-linked recessive pattern, predominantly affecting males. Repeated bleeding episodes can lead to joint damage and muscle hemorrhages over time. Symptoms include frequent nosebleeds, easy bruising, and excessive bleeding from minor cuts or injuries. Joint bleeding is a common issue, causing pain and swelling.